SGMT - Sagimet Biosciences Inc.
5.86
-0.010 -0.171%
Share volume: 252,135
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.87
-0.01
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-15-2024 | 08-14-2024 | 11-14-2024 | 03-12-2025 | 05-08-2025 | 11-13-2025 | 03-11-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 8.768 M | 10.589 M | 16.902 M | 18.195 M | 19.865 M | 14.334 M | 10.765 M | |
| Selling general and admin | 3.506 M | 4.276 M | 4.249 M | 3.979 M | 4.523 M | 4.604 M | 4.031 M | |
| Research and development | 5.262 M | 6.313 M | 12.653 M | 14.216 M | 15.342 M | 9.730 M | 6.734 M | |
| Total expenses | 8.768 M | 10.589 M | 16.902 M | 18.195 M | 19.865 M | 14.334 M | 10.765 M | |
| 20.77% | 59.62% | 7.65% | 9.18% | -27.84% | -24.90% | |||
| Operating income | -8.768 M | -10.589 M | -16.902 M | -18.195 M | -19.865 M | -14.334 M | -10.765 M | |
| Ebit | -8.768 M | -10.589 M | -16.902 M | -18.195 M | -19.865 M | -14.334 M | -10.765 M | |
| Pretax income | -6.629 M | -8.118 M | -14.619 M | -16.201 M | -18.176 M | -12.908 M | -9.568 M | |
| 22.46% | 80.08% | 10.82% | 12.19% | -28.98% | -25.88% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -6.629 M | -8.118 M | -14.619 M | -16.201 M | -18.176 M | -12.908 M | -9.568 M | |
| -22.46% | -80.08% | -10.82% | -12.19% | 28.98% | 25.88% |